Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cytosorbents Corporation before investing.

In this article, we go over a few key elements for understanding Cytosorbents Corporation’s stock price such as:

• Cytosorbents Corporation’s current stock price and volume
• Why Cytosorbents Corporation’s stock price changed recently
• Upgrades and downgrades for CTSO from analysts
• CTSO’s stock price momentum as measured by its relative strength

About Cytosorbents Corporation (CTSO)

Before we jump into Cytosorbents Corporation’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Want to learn more about Cytosorbents Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cytosorbents Corporation.

Cytosorbents Corporation’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, Cytosorbents Corporation’s stock price was $0.370.

Cytosorbents Corporation is up 18.93% from its previous closing price of $0.311.

During the last market session, Cytosorbents Corporation’s stock traded between $0.311 and $0.380. Currently, there are approximately 62.81 million shares outstanding for Cytosorbents Corporation.

Cytosorbents Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cytosorbents Corporation Stock Price History

Cytosorbents Corporation’s (CTSO) price is currently up 2.52% so far this month.

During the month of August, Cytosorbents Corporation’s stock price has reached a high of $0.400 and a low of $0.300.

Over the last year, Cytosorbents Corporation has hit prices as high as $1.040 and as low as $0.300. Year to date, Cytosorbents Corporation’s stock is down 42.12%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cytosorbents Corporation Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 21, 2026, there were analysts who downgraded Cytosorbents Corporation’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Cytosorbents Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cytosorbents Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cytosorbents Corporation (CTSO) by visiting AAII Stock Evaluator.

Relative Price Strength of Cytosorbents Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 21, 2026, Cytosorbents Corporation has a weighted four-quarter relative price strength of -21.10%, which translates to a Momentum Score of 10 and is considered to be Very Weak.

Want to learn more about how Cytosorbents Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cytosorbents Corporation Stock Price: Bottom Line

As of August 21, 2026, Cytosorbents Corporation’s stock price is $0.370, which is up 18.93% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cytosorbents Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.